Hypomethylation of Thyroid Peroxidase as a Biomarker for Hepatocellular Carcinoma with Tumor Thrombosis

Abstract

Objective

Thyroid hormones (THs) regulate multiple physiological activities in the liver, including cellular metabolism, differentiation, and cell growth, and play important roles in the pathogenesis of hepatocellular carcinoma (HCC). Thyroid peroxidase (TPO) is a key molecule involved in the THs synthesis and signaling pathway. As an epigenetic modification, DNA methylation has a critical role in tumorigenesis with diagnostic potential. However, the connection between THs and DNA methylation has been rarely investigated.

Methods

The methylation of key TH-related genes was analyzed by in-house epigenome-wide scanning, and we further analyzed the methylation levels of the TPO promotor in 164 sample pairs of HCC and adjacent non-cancerous tissues by Sequenom EpiTYPER assays, and evaluated their clinical implications.

Results

We identified that the methylation of the TPO promoter was downregulated in the HCC tissues (P<0.0001) with a mean difference ranging from 18.5% to 22.3%. This methylation pattern correlated with several clinical factors, including a multi-satellite tumor, fibrous capsule, and the presence of tumor thrombus. The receiver operator characteristic (ROC) curve analysis further confirmed that the percent methylated reference (PMR) values for TPO were predictive of the tumor [the area under the curve (AUC) ranged from 0.755 to 0.818] and the thrombosis in the HCC patients (the AUC ranged from 0.706 to 0.777).

Conclusion

These findings demonstrated that epigenetic alterations of TPO, as indicated by the PMR values, were a potential biomarker for HCC patients with tumor thrombosis.

Keywords

thyroid hormones / thyroid peroxidase / hepatocellular carcinoma / methylation / tumor thrombosis

References

[1] El-SeragHB, RudolphKL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132(7): 2557-2576

[2] JemalA, BrayF, CenterMM, et al.. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90

[3] EggerG, LiangG, AparicioA, et al.. Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004, 429(6990): 457-463

[4] BjornssonHT, FallinMD, FeinbergAP. An integrated epigenetic and genetic approach to common human disease. Trends Genet, 2004, 20(8): 350-358

[5] StefanskaB, HuangJ, BhattacharyyaB, et al.. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res, 2011, 71(17): 5891-5903

[6] ShenJ, WangS, ZhangYJ, et al.. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology, 2012, 55(6): 1799-1808

[7] RevillK, WangT, LachenmayerA, et al.. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology, 2013, 145(6): 1424-1435 e1421–1425

[8] ShenJ, WangS, ZhangYJ, et al.. Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips. Epigenetics, 2013, 8(1): 34-43

[9] SongMA, TiirikainenM, KweeS, et al.. Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS One, 2013, 8(2): e55761

[10] NishidaN, NishimuraT, NakaiT, et al.. Genome-wide profiling of DNA methylation and tumor progression in human hepatocellular carcinoma. Dig Dis, 2014, 32(6): 658-663

[11] MannDA. Epigenetics in liver disease. Hepatology, 2014, 60(4): 1418-1425

[12] HardyT, MannDA. Epigenetics in liver disease: from biology to therapeutics. Gut, 2016, 65(11): 1895-1905

[13] WuSM, ChengWL, LinCD, et al.. Thyroid hormone actions in liver cancer. Cell Mol Life Sci, 2013, 70(11): 1915-1936

[14] WangT, XiaL, MaS, et al.. Hepatocellular carcinoma: thyroid hormone promotes tumorigenicity through inducing cancer stem-like cell self-renewal. Sci Rep, 2016, 6: 25183

[15] LinYH, LiaoCJ, HuangYH, et al.. Thyroid hormone receptor represses miR-17 expression to enhance tumor metastasis in human hepatoma cells. Oncogene, 2013, 32(38): 4509-4518

[16] ChenCY, ChungIH, TsaiMM, et al.. Thyroid hormone enhanced human hepatoma cell motility involves brain-specific serine protease 4 activation via ERK signaling. Mol Cancer, 2014, 13: 162

[17] ChungIH, ChenCY, LinYH, et al.. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer. Oncotarget, 2015, 6(17): 15050-15064

[18] DaiB, GengL, YuY, et al.. Methylation patterns of estrogen receptor alpha promoter correlate with estrogen receptor alpha expression and clinicopathological factors in hepatocellular carcinoma. Exp Biol Med (Maywood), 2014, 239(7): 883-890

[19] NishidaN, GoelA. Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics, 2011, 12(2): 130-137

[20] PortelaA, EstellerM. Epigenetic modifications and human disease. Nat Biotechnol, 2010, 28(10): 1057-1068

[21] BaylinSB, ChenWY. Aberrant gene silencing in tumor progression: implications for control of cancer. Cold Spring Harb Symp Quant Biol, 2005, 70: 427-433

[22] RufJ, CarayonP. Structural and functional aspects of thyroid peroxidase. Arch Biochem Biophys, 2006, 445(2): 269-277

[23] ZhangH, YeJ, WengX, et al.. Comparative transcriptome analysis reveals that the extracellular matrix receptor interaction contributes to the venous metastases of hepatocellular carcinoma. Cancer Genet, 2015, 208(10): 482-491